https://scholars.lib.ntu.edu.tw/handle/123456789/635377
Title: | Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells | Authors: | SHANG-JU WU Lin, Chien-Ting Liao, Cheng Hao Lin, Chun-Ming |
Keywords: | Bispecific antibody; Blinatumomab; CD19-targeting; γ9δ2 T cells | Issue Date: | May-2023 | Journal Volume: | 31 | Start page/Pages: | 101650 | Source: | Translational oncology | Abstract: | Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar application. First, we showed that γ9δ2 T cells could serve as effector cells for blinatumomab, and these effector memory cells could survive for at least 7 days after infusion. The genetically modified blinatumomab-secreting γ9δ2 T cells induced significant cytotoxicity in CD19+ tumor cell lines and primary cells from chronic lymphocytic leukemia patients. Of note, blinatumomab-secreting γ9δ2 T cells might also exhibit dual-targeting of CD19 and isopentenyl pyrophosphate, a universal tumor-associated antigen. Furthermore, blinatumomab-secreting γ9δ2 T cells killed CD19-transfected adherent cells, suggesting that the γ9δ2 T cells might be effective for treating solid tumors with appropriate cancer antigens. Together, these results demonstrate the promise of blinatumomab-secreting γ9δ2 T cells as a cancer therapy. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85149748638&doi=10.1016%2fj.tranon.2023.101650&origin=inward&txGid=d8e0cff7db05d68479151e3f999d4b9b https://scholars.lib.ntu.edu.tw/handle/123456789/635377 |
ISSN: | 1936-5233 | DOI: | 10.1016/j.tranon.2023.101650 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.